Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 270 participants.
Also called NCT05565976
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 270 participants
- Registry
-
NCT05565976
-
- Other papers using this trial's data
- The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Unknown status
Technical summary
Registry record NCT05565976. Randomized; triple masking; primary purpose prevention. Start 2020-08-01 (actual); primary completion 2024-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
- Acronym
- DECIST
- Condition
- Stroke, Ischemic
- Condition
- Mild Cognitive Impairment
- Condition
- Dementia, Vascular
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Drug)
- Statins (Cardiovascular Agents)
- Intervention (Drug)
- Platelet Antiaggregant
- Intervention (Drug)
- Antidiabetic
- Lead sponsor
- Jaime Daniel Mondragon
- Collaborator
- Hospital General León
- Collaborator
- Hospital General de Zona IMSS N0. 21
- Collaborator
- University Medical Center Groningen
Record details
- Record id
cardio:ct-nct05565976- Content hash
d61dc76253e11f749dfbfeb67c3a75323b9fd896b57d4b2116d8de736a57a031